These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37614090)

  • 1. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
    Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
    Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
    Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
    [No Abstract]   [Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
    Tancoš V; Grendár M; Farkašová A; Huťka Z; Kviatkovská Z; Plank L
    Klin Onkol; 2020; 33(1):55-65. PubMed ID: 32075390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
    De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
    J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Gagné A; Orain M; Ionescu D; Tsao MS; Joubert D; Joubert P
    Lung Cancer; 2020 Aug; 146():276-284. PubMed ID: 32593917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
    Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
    Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
    Butter R; Hondelink LM; van Elswijk L; Blaauwgeers JLG; Bloemena E; Britstra R; Bulkmans N; van Gulik AL; Monkhorst K; de Rooij MJ; Slavujevic-Letic I; Smit VTHBM; Speel EM; Thunnissen E; von der Thüsen JH; Timens W; van de Vijver MJ; Yick DCY; Zwinderman AH; Cohen D; 't Hart NA; Radonic T
    Lung Cancer; 2022 Apr; 166():143-149. PubMed ID: 35279453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
    van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
    Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
    Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
    J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples.
    Ilié M; Hofman V; Bontoux C; Goffinet S; Benzaquen J; Heeke S; Boutros J; Lassalle S; Long-Mira E; Zahaf K; Lalvée S; Lespinet-Fabre V; Bordone O; Tanga V; Gómez-Caro A; Cohen C; Berthet JP; Marquette CH; Hofman P
    Lung Cancer; 2023 Jul; 181():107230. PubMed ID: 37150140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer.
    Fu F; Deng C; Sun W; Zheng Q; Jin Y; Li Y; Zhang Y; Chen H
    Respir Res; 2022 Nov; 23(1):302. PubMed ID: 36335353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.